Analyzing Vericel (NASDAQ:VCEL) and Gain Therapeutics (NASDAQ:GANX)

Vericel (NASDAQ:VCEL) and Gain Therapeutics (NASDAQ:GANX) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their risk, institutional ownership, earnings, dividends, valuation, analyst recommendations and profitability.

Volatility & Risk

Vericel has a beta of 1.02, meaning that its share price is 2% more volatile than the S&P 500. Comparatively, Gain Therapeutics has a beta of 0.19, meaning that its share price is 81% less volatile than the S&P 500.

Institutional and Insider Ownership

12.0% of Gain Therapeutics shares are owned by institutional investors. 7.6% of Vericel shares are owned by company insiders. Comparatively, 4.2% of Gain Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Vericel and Gain Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Vericel	7.91%	6.91%	5.02%
Gain Therapeutics	N/A	-161.59%	-118.36%

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Vericel and Gain Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vericel	0	2	4	0	2.67
Gain Therapeutics	1	0	4	0	2.60

Vericel presently has a consensus target price of $58.40, suggesting a potential upside of 44.91%. Gain Therapeutics has a consensus target price of $7.67, suggesting a potential upside of 443.74%. Given Gain Therapeutics’ higher probable upside, analysts plainly believe Gain Therapeutics is more favorable than Vericel.

Valuation & Earnings

This table compares Vericel and Gain Therapeutics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vericel	$306.30 million	6.74	$16.52 million	$0.47	85.74
Gain Therapeutics	$50,000.00	1,230.65	-$20.16 million	($0.50)	-2.82

Vericel has higher revenue and earnings than Gain Therapeutics. Gain Therapeutics is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks.

Summary

Vericel beats Gain Therapeutics on 10 of the 13 factors compared between the two stocks.

About Vericel

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.

About Gain Therapeutics

Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. The company's lead drug candidate, GT-02287 for the treatment of GBA1 Parkinson's disease is being evaluated in a Phase I clinical trials. It also has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of Dementia with Lewy Bodies, Alzhiemer's Disease, Gaucher, GM1 Gangliosidosis, Krabbe Disease, Alpha1-Antitrypsun deficiency, and solid tumors. Gain Therapeutics, Inc. was founded in 2017 and is headquartered in Bethesda, Maryland.